Table S1. Primers used for PCR

Gene	Forward Primer	Reverse Primer	
HS KLK5	CACAAGGGTAATCTCCCCAG	AGATGACACCATGTTCTGCG	
HS KLK7	GGGTACCTCTGCACACCAAC	GGATGTCAAGCTCATCTCCC	
HS ACTB	ACCTTCTACAATGAGCTGCG	CCTGGATAGCAACGTACATGG	
MM Klk5	GAACCACTTAGCCTCGACCTTTAT	GTTCGGTTCCAGAGGGGTTG	
MM Klk7	GTGCTGGCATTCCTGACTCTA	CCATCACCCACCGTTTGTACT	
MM Gapdh	CCCAGCAAGGACACTGAGCAA	TTATGGGGGTCTGGGATGGAAA	
MM Il4ra	GTTACAGGAACAAGACCAGCA	TGGAGCCTGAACTCGCA	
MM Il4	GAACGAGGTCACAGGAGAAG	ACCTTGGAAGCCCTACAGA	
MM 1113	TGCCATCTACAGGACCCAGA	CTCATTAGAAGGGGCCGTGG	

CICATT

Antibody	Vendor	Catalog #	Antibody	Vendor	Catalog #		
CD49b APC	Biolegend	17-5971-82	Siglec-F BV421	BD	562681		
CD11b BV510	Biolegend	101245	CD117 BV605	Biolegend	135122		
CD3ε PerCP/Cy5.5	eBioscience	45-0031-82	CD5 PerCP/Cy5.5	eBioscience	45-0051-82		
CD11c PerCP/Cy5.5	eBioscience	45-0114-82	CD19 PerCP/Cy5.5	eBioscience	45-0193-82		
NK1.1 PerCP/Cy5.5	eBioscience	45-5941-82	ST2-Biotin	Biolegend	145307		
KLRG1 PE/Dazzle	Biolegend	138424	CD25 BV605	Biolegend	102035		
FcεRIα FITC	eBioscience	11-5898-85	IgE FITC	eBioscience	11-5992-81		
CD90.2 PE/Cy7	Biolegend	140309	CD45 APC	Biolegend	103111		
CD45.2 PE	Biolegend	109808	CD3e PE	Biolegend	100307		
Johnal							

Table S2. Primary antibodies for flow cytometry





c Pearson correlation









outine prevention of the second secon



ournal Propool



SUPPLEMENTAL TEXT

Figure S1. *KLK7*, but not *KLK5*, is upregulated in human lesional AD skin. **a.** Log2 read counts per million (CPM) of *KLK5* in control skin from donors without AD (N=20, age = 36.8 ± 2.4 years, 42.9% female), and matched pairs of non-lesional (NL) skin and lesional (LS) skin from donors with AD (N=35, age = 34.3 ± 2.5 years, 50% female). **b.** Log2 CPM of *KLK7* in the same RNA-seq data set. Note that *KLK7* is overexpressed only in lesional AD skin. n.s. no significance. * p<0.05. ** p<0.01. **c**. Pearson correlation between KLK7 transcript abundance in lesional skin and the Visual Analog Scale (VAS) itch scores from AD patients. R = 0.22 (CI -0.13 - 0.52), p = 0.22.

Figure S2. *Klk7* expression is restricted to the epidermis in mouse skin. **a**. Genomic construct of the *Klk7*^{tm1(KOMP)Vlcg} allele. Exons 3-5 within the coding region of *Klk7* is replaced with a *LacZ-β-galactosidase* reporter. **b**. X-gal staining (blue) of hair-bearing skin from a *Klk7*^{LacZ} mouse, in which LacZ expression is controlled under the *Klk7* promoter. **c-f**. X-gal staining of **c**. dorsal root ganglia (DRG), **d**. trigeminal ganglia (TG), **e**. spinal cord, **f**. and brain. **g**. RT-PCR screening of *Klk7* expression in tissues from a WT control mouse. n = 3 biological replicates for panels **b-g**. H. Skin = hairy skin. G. Skin = glabrous skin. SI = Small intestine.

Figure S3. $Klk7^{-/-}$ mice do not show lowered Th2 and inflammatory markers after MC903 Treatment. **a-b.** ELISA based quantification of serum **a.** IgE and **b.** TARC levels in MC903 treated control and $Klk7^{-/-}$ mice. **c-e.** RT-qPCR quantification of **c.** $ll4r\alpha$, **d.** ll4, and **e.** ll13 expression in MC903 treated skin of control and $Klk7^{-/-}$ mice. **f.** RT-qPCR quantification of Tslp expression in vehicle or MC903 treated skin of control and $Klk7^{-/-}$ mice. **n.**s. no significance. *** p<0.001

Figure S4. rhKLK7 does not activate PAR2 receptors. Representative calcium transients of KRNK cells stably transduced with PAR2 expression after treatment with rhKLK7 and Trypsin.

Figure S5. Acute *in vivo* and *in vitro* effects of rhKLK7. a.-b. Acute pain (wiping) and itch (scratching) behavioral responses of C57BL/6J mice to v 'n.s. or 1 µg rhKLK7 injections. c. Quantification of calcium responses of culture DRG neurons from $Pirt^{GCaMP/+}$ mice to acute application of vehicle or 20 ng/µl rhKLK7. Percent responsive represents fraction of all DRG neurons in field. Data is presented as mean ± SEM. Statistical significance was determined using two tailed Student's *t* test. n.s. denotes no significance.